Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Zelensky confidant dismissed from further posts amid bribery scandal - 2This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- 3The cheap health insurance promoted by Trump officials has this catch
- 4Gunmen open fire near Israeli consulate in Istanbul in possible ISIS-linked attack
- 51st human missions to Mars should hunt for signs of life, report says
- Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon
- Private sector revives the climate disaster database Trump tried to squash
- Inflammatory Merz remarks on migrants' violence against women slammed
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
